Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News on Pharma

The war on kush: The synthetic drug sweeping through parts of Africa

A new report by an anti-transnational crime group has identified the core chemical components of kush, a synthetic drug that has swept through Sierra Leone and the region in the past few years.

The Independent UK

The Latest: Musk renews threat to fire federal workers despite pushback from various agencies

Elon Musk is vowing yet again to fire any federal workers who don’t respond to an email asking them to list five things they accomplished last week

The Independent UK

Biological E Limited partners with Bavarian Nordic to increase global access to Chikungunya Vaccine

This partnership comprises a technology transfer of the current drug product manufacturing process for the Chikungunya Vaccine, with the option to transfer the drug substance process at a later stage. Read further on Dynamite News:

Dynamite News

From analysis to the latest developments in health,
read the most diverse news in one place.

Why has Unilever CEO Hein Schumacher stepped down and who is replacing him?

Mr Schumacher was named CEO in 2023 following the retirement of Alan Jope but has now stepped down in a surprise move

Evening Standard

3 Pharmaceutical Stocks With Blockbuster Drug Potential

The pharma industry is delivering game-changing therapies with favorable regulatory support. Amid this backdrop, investors might consider adding three well-positioned biotech stocks such as Vertex Pharmaceuticals (VRTX), BioMarin Pharmaceutical (BMRN), and Gilead Sciences (GILD), for potential gains. Learn more….

StockNews.com

3 Biotech Stocks Revolutionizing Healthcare

Biotech stocks are revolutionizing healthcare with breakthrough innovations, leading the charge in precision therapies and transformative partnerships. To capitalize on this trend, consider adding Amgen (AMGN), BioNTech (BNTX), and Gilead Sciences (GILD), which could boost your portfolio.

StockNews.com

Is a new painkiller too good to be true?

Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids

Salon

Read news from The Economist, FT, and more,
with one subscription

AstraZeneca, Whitehall, and a failed £450m deal for the next generation in vaccines. What went wrong?

When the pharma firm cancelled plans for a major expansion of its Merseyside plant last month, there was no shortage of questions – or blame – over responsibility

The Guardian - UK

Eli Lilly Stock Rises After Profit, Outlook Top Expectations

Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 guidance. Here's what you need to know.

Kiplinger

AstraZeneca ‘very disappointed’ after ditching £450m Liverpool vaccine site

Pascal Soriot, chief executive of AstraZeneca, denied any rift with the Government over the decision.

The Independent UK

Is Harmony Biosciences Holdings Inc. (HRMY) a Biotech Stock to Consider?

Harmony Biosciences’ (HRMY) recently released growth plans and pipeline advancements have showcased the company’s dedication towards being a top contender in the highly contested biotech market. So, should investors looking to capitalize on the industry’s prospects consider investing in HRMY? Read more….

StockNews.com

AstraZeneca ‘very disappointed’ over axed £450m Liverpool vaccine project

As drugmaker reports 38% jump in profits, CEO denies tension with UK government after Speke plant decision

The Guardian - UK

Drug firm GSK delivers a syringe full of crowd-pleasers

Pharmaceuticals company’s higher dividend, upgrade to revenues and share buyback suggest its drugs pipeline is flowing nicely

The Guardian - UK

Novo Nordisk confident despite Trump tariff risk as sales of weight-loss jab soar

Europe’s biggest firm, whose sales of Wegovy almost doubled, feels it can ‘meet demands’ of US administration

The Guardian - UK

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - UK

AstraZeneca’s U-turn on £450m Speke expansion ‘deeply disappointing’, says minister

Chris Bryant says reduction of government support was linked to change in drugmaker’s proposed investment

The Guardian - UK

AstraZeneca’s £450m Speke U-turn looks terrible for a pro-growth government

It seems bizarre that ministers and UK’s largest company cannot complete investment in vital life sciences sector

The Guardian - UK

AstraZeneca axes £450m vaccine plant in Liverpool, blaming state funding cut

Days after Rachel Reeves highlighted life sciences as UK strength, firm decides against site expansion

The National (Scotland)

Suspected drug deaths in Scotland down by 10 per cent, latest figures show

Suspected drugs deaths have fallen by 10 per cent in the latest quarterly data, with drug-related attendances at A&E seeing a similar decrease.

Get all your
news in one place.

100’s of premium titles.
One news app.

Top News

Vivek Ramaswamy To Run For Ohio Governor In 2026

Vivek Ramaswamy, with support from JD Vance's team, gears up for the 2026 Ohio gubernatorial race in a competitive GOP landscape.

The Guardian - UK

Wegovy maker Novo Nordisk rebuked by watchdog over failure to disclose payments to UK health groups

Danish drug giant found to have failed to accurately report spending even after admitting to errors

Kiplinger

Novo Nordisk Stock Surges On Weight Loss Drug Data and Analysts Say It's Still a Buy

Novo Nordisk stock is paring its year-over-year deficit on positive early stage trial results for the company's new weight loss drug. Here's what you need to know.

The Independent UK

Sackler family to pay $6.5 billion for their role in ‘fueling’ opioid epidemic which has killed hundreds of thousands

Sackler family, who owned pharmaceutical company Purdue Pharma, will no longer be in control of the company or permitted to sell opioids if the new settlement plan is approved

The Independent UK

Purdue Pharma and owners to pay $7.4 billion in settlement to lawsuits over the toll of OxyContin

Members of the Sackler family who own OxyContin maker Purdue Pharma, and the company itself, agreed to pay up to $7.4 billion to settle lawsuits over the toll of the powerful prescription painkiller

International Business Times

Sacklers, Purdue To Pay $7.4 Bn Over Opioid Crisis

Several US states have reached a $7.4 billion settlement with the Sackler family and their pharmaceutical company Purdue over the opioid crisis that has ravaged the lives of millions of Americans, officials said Thursday.

The Guardian - US

Purdue Pharma and Sacklers reach new $7.4bn settlement over opioids crisis

Settlement resolves thousands of lawsuits alleging Oxycontin caused addiction crisis

1 … 23 24 25 26

People

Lars Fruergaard Jørgensen

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.